The improvement will be because of maiden earnings contribution from Acumen Diagnostics (Acumen), in which Aoxin has a 49% stake.
See also: StarHub’s weak FY2026 guidance leads DBS to review call while Morningstar flags overvaluation
Aoxin can also expect an improved performance of its core dental business, which should start contributing earnings of about RMB6 million in 2022, from a potential loss in 2021.
Cheong also expects Aoxin to have the potential to expand into providing Covid-19 ART testing services, further lifting its earnings.
The company is already providing Polymerase Chain Reaction (PCR) testing and has “a respectable market.”
See also: IFAST share price dips despite strong earnings 4QFY2025 announcement; DBS maintains ‘buy’ at $12
For more stories about where the money flows, click here for our Capital section
On an assumption of a 10% market share and a 40% net margin, this new business could contribute an additional $9 million to Aoxin’s FY2022 earnings, potentially lifting 2022 earnings by another 80%.
Aoxin shares traded at 26.5 cents as at 10.47 am, down 1.85%.
